How aged blood can trigger cellular aging in young mice

Aging is usually described as something that accumulates inside tissues over time. A 2022 experiment in male mice tested a different possibility: can the circulation of an old animal push young tissues toward a senescent state after a single exchange of blood?

The answer was yes for several of the measurements the researchers used. Young mice that received blood from naturally aged mice developed increased signs associated with cellular senescence in skeletal muscle, kidney, and liver. When the old donors were treated with drugs that remove senescent cells before the exchange, several of those changes were reduced.

The result is not evidence that a young mouse suddenly became old, or that an established aging process was reversed in an old one. Its importance is narrower and more precise. The experiment connected naturally aged blood with a rapid, tissue-selective response in young recipients, then used donor treatment to test whether senescent cells in the old animals contributed to that response.

What the blood exchange was designed to isolate

The study used heterochronic blood exchange, meaning blood was transferred between animals of different ages. The young recipients were about three months old, while the old donors were about 22 to 24 months old. A young-to-young exchange served as the comparison.

This arrangement matters because it separates circulating influences from several features of heterochronic parabiosis, in which a young and old animal are surgically joined. Parabiosis can involve shared blood, but also shared organs, oxygenation, blood pressure, nutrition, physical activity, and surroundings. The blood-exchange procedure did not join the animals’ organs or environments. It asked a more focused question: what changes follow when the recipient’s circulation is exposed to blood from an older animal?

The researchers tracked a reporter associated with p16, a protein commonly used in studies of senescence. Senescent cells have entered a lasting halt in cell division and can release a collection of signaling molecules known as the senescence-associated secretory phenotype, or SASP. Those secretions can influence nearby cells and tissues, so the central concern was whether physiologically aged blood could spread a senescence-related state beyond the cells where it first arose.

Fourteen days after the exchange, young recipients exposed to old blood showed a significant increase in whole-body reporter activity compared with young mice that received blood from young donors. That timing made the result notable: the response appeared after one exchange, rather than requiring years of additional aging or an artificial injury such as radiation.

Senescence showed up in selected tissues

The glowing reporter was only the starting point. In muscle, kidney, and liver, the old-blood group also showed increases in several senescence-associated measurements. These included changes in Cdkn2a and Cdkn1a, genes linked to cell-cycle arrest, along with SASP-related messages such as Il6, Mmp3, Mmp13, Il1a, Il1b, Tnfa, Cxcl1, and other tissue-specific factors.

The pattern was not uniform across the body. The reported gene changes were detected in selected tissues rather than in every organ examined; the comparison did not show the same response in lung, heart, or hippocampus. This selectivity matters because it argues against treating the experiment as a simple whole-body switch. Different tissues contain different cell populations, local environments, and sensitivities to circulating signals.

Additional staining supported the tissue response. The affected muscle, kidney, and liver showed more cells positive for SA-β-gal, another senescence-associated measurement, as well as more γ-H2AX foci and less nuclear HMGB1 in the reported assays. None of these markers is a complete definition of senescence on its own. Used together with the reporter, gene measurements, and tissue-specific patterns, however, they made the interpretation stronger than a change in one fluorescent or luminescent signal.

Muscle provided an especially informative example. The researchers found p16-positive, Pax7-positive satellite cells in young muscle after exposure to blood from untreated old donors. Satellite cells help maintain and repair skeletal muscle, so their appearance in a senescent state connected the circulating exposure to a cell population with a direct role in tissue upkeep. Treating the old donors before exchange reduced the number of these senescent satellite cells and other senescence-associated cells in young muscle.

The functional effects were uneven too

The molecular and staining results were accompanied by selected changes in performance and tissue injury. Young mice that received old blood showed weaker muscle contractions, altered force development and relaxation, greater fatigability, and shorter treadmill running distances in the reported tests. Intramuscular lipid also increased, while fibrosis was not changed in the same comparison.

Kidney findings illustrated why marker changes, structural injury, and organ performance need to be kept separate. Young recipients exposed to old blood had higher levels of kidney injury molecule-1, or KIM-1, and neutrophil gelatinase-associated lipocalin. They also lost some of the healthy brush-border staining associated with proximal kidney tubules. At the same time, the exchange did not produce obvious structural changes in the kidney on the reported examinations, and blood urea nitrogen and creatinine did not change in the same way.

That combination is not contradictory. A tissue can show molecular signs of stress or injury before a broad structural abnormality becomes visible, and a marker of proximal-tubule damage is not interchangeable with a general measure of kidney filtration. The experiment therefore supports a selected pattern of tissue effects rather than a claim that every aspect of organ function changed together.

Treating the old donor changed the experiment

The strongest causal test came before the blood exchange. The researchers treated old mice with senolytic drugs, which are intended to eliminate senescent cells, and then transferred their blood to young recipients. One regimen combined dasatinib and quercetin. Another used navitoclax, also called ABT263. These treatments act through different pathways, and their effects were not identical across every measurement.

Blood from treated old donors contained lower levels of several SASP-associated factors. After exchange, young mice that received blood from dasatinib-plus-quercetin-treated donors showed reduced senescence-associated changes in kidney and liver compared with young mice that received blood from vehicle-treated old donors. KIM-1 declined and healthy tubular staining was better preserved in some kidney measurements. Liver fibrosis, adiposity, and several pro-fibrogenic gene signals were also attenuated.

Navitoclax produced a related pattern in the reported comparisons. Young recipients showed lower whole-body reporter activity and reduced senescence-associated gene, staining, and tissue-injury measurements in kidney and liver when the old donors had received the drug. The platelet measurements included in the experiment helped the researchers examine whether the result could simply be explained by a major reduction in platelets, a possible complication of navitoclax. The reported platelet counts were not significantly decreased 14 days after the last dose.

The overlap between the two donor treatments supports the idea that senescent cells in old animals contribute to the transferable effect. It does not mean that either drug completely removed every relevant cell, that the treatments had identical biology, or that all recipient outcomes were rescued. In the dasatinib-plus-quercetin comparison, donor treatment improved some kidney injury-related measurements while blood urea nitrogen, creatinine, and reported pathological changes remained negatively affected.

Protection of young tissue is not reversal of old tissue

The study included a comparison that set a crucial boundary around the donor-treatment result. The researchers exchanged blood between old animals and compared old recipients exposed to blood from vehicle-treated or navitoclax-treated old donors.

In already old recipients, treating the donor did not reverse the reported senescence markers, loss of muscle strength, renal damage, liver fibrosis, or poor physical endurance. The strategy that reduced some newly imposed changes in young recipients therefore did not restore an aged recipient to a younger state in the old-to-old experiment.

Recipient age changes the biological problem. A young mouse exposed to an aged circulation is being challenged by a new external influence while much of its tissue environment remains young. An old mouse already carries accumulated tissue changes and other age-related factors. Removing some senescent cells from the donor may reduce what is transferred without erasing the recipient’s existing conditions.

This is why the experiment is better understood as evidence for interrupting a harmful communication pathway than as evidence for a general rejuvenation treatment. It also leaves room for senescence-unrelated factors in old blood, since donor senolytic treatment did not reproduce every benefit associated with exposure to young blood and did not repair established deficits in old recipients.

The circulating carrier remained unresolved

The experiment established a circulating influence more clearly than it identified the thing carrying that influence. The authors left open several possibilities, including soluble molecules, exosomes, transferred senescent cells, or a combination. Comparative protein measurements pointed to TGF-β1 as one possible pro-aging factor, but the study did not reduce the entire effect to one confirmed molecule.

The human part of the work was also limited but useful as a bridge. Primary human renal epithelial cells were cultured with plasma from younger adults, ages 20 to 30, or older adults, ages 60 to 70. Within the culture experiment, older plasma induced or tended to induce several senescence-associated measurements, including SA-β-gal activity, CDKN2A and CDKN1A messenger RNA, IL1A messenger RNA, and secreted IL-6. The response varied by cell type and marker, and some measurements were not induced in the same way.

Cultured cells exposed to human plasma are not a substitute for a study of blood circulation in living people. They show that selected human cells can respond to an aged plasma environment under laboratory conditions, not that senescence spreads systemically through people or that a senolytic treatment would be safe or beneficial for them.

The mouse design also had limits. It used only male mice, a choice the authors made to avoid additional variability associated with daily hormonal changes. Group size was based on a previous study rather than statistical sample-size predetermination. Those details do not erase the observed patterns, but they help define how broadly the findings should be generalized.

What this could change

If the circulating contribution of senescent cells can be confirmed and safely interrupted, future treatments might protect muscle and organ function by reducing harmful communication from an aged blood environment. People vulnerable to age-related loss of strength or organ resilience could eventually benefit from such an approach, but only after a durable intervention works in already aged organisms and translates safely to humans.

The July 2022 result made that possibility more concrete by linking donor-cell treatment to a reduced response in young recipients. Its practical promise depended on solving the unresolved carrier problem, separating helpful effects from unwanted ones, and showing that the strategy can preserve function rather than merely shift laboratory markers. The immediate advance was a way to test how aging-related cellular changes move through the circulation, not a ready-made therapy.

Key Sources

• Primary source: Systemic induction of senescence in young mice after single heterochronic blood exchange.
  DOI or Journal Page · Peer-Reviewed Paper · 2022-07-28